A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

PHASE1RecruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

August 28, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

April 5, 2027

Conditions
Diffuse Large B-Cell LymphomaHigh-grade B-cell Lymphoma
Interventions
DRUG

Loncastuximab Tesirine

Intravenous (IV) Infusion

Trial Locations (14)

100

RECRUITING

National Taiwan University Hospital, Taipei

41944

RECRUITING

Kyungpook National University Chilgok Hospital, Daegu

90262

COMPLETED

The Oncology Institute of Hope & Innovation - Lynwood, Lynwood

70200-730

RECRUITING

Hospital Sírio-Libanês - Brasília, Brasília

90110-270

RECRUITING

Hospital Mãe de Deus - Centro Integrado de Oncologia, Porto Alegre

01308-050

RECRUITING

Hospital Sírio-Libanês - São Paulo, São Paulo

01323-030

RECRUITING

A Beneficência Portuguesa de São Paulo - Unidade Mirant, São Paulo

01409-002

RECRUITING

Hospital 9 de Julho, São Paulo

05652-900

RECRUITING

Albert Einstein Israelite Hospital, São Paulo

602-812

RECRUITING

Dong-A University Hospital, Pusan

02841

ACTIVE_NOT_RECRUITING

Korea University Anam Hospital, Seoul

03080

RECRUITING

Seoul National University Hospital, Seoul

03722

RECRUITING

Severance Hospital, Seoul

Taiwan 112

RECRUITING

Koo Foundation Sun Yat-Sen Cancer Center, Taipei

Sponsors
All Listed Sponsors
lead

ADC Therapeutics S.A.

INDUSTRY